Petros Grivas , MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Targeted Therapy
Dr. Petros Grivas is a medical oncologist from Cleveland,Ohio and he works at several hospitals in the area, such as Cleveland Clinic. He did his Medical Schooling from University of Patras School of Medicine and Residency in Internal Medicine from Drexel University - Hahnemann University Hospital. The doctor is certified in Medical Oncology & Internal Medicine from American Board of Internal Medicine and has an experience of more than 19 years.
University of Patras School of Medicine
Medical School
Drexel University - Hahnemann University Hospital
Residency
University of Michigan Hospitals and Health Centers
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
MI State Medical License Active through 2017
OH State Medical License Active through 2019
CLEVELAND CLINIC HOSPITAL
Languages: English/Spanish
(216) 445-0150
9500 Euclid Ave Taussig Cancer Institute
Read MoreCancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?
Grivas, P.,Koshkin, V. S.,Pal, S. K.; Ann. Oncol.. 2017 Mar 23.
See more >>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar, A. V.,Galsky, M. D.,Rosenberg, J. E.,Powles, T.,Petrylak, D. P.,Bellmunt, J.,Loriot, Y.,Necchi, A.,Hoffman-Censits, J.,Perez-Gracia, J. L.,Dawson, N. A.,van der...; Lancet. 2016 Dec 13.
See more >>Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P, Galsky MD, Bellmunt J, Sonpavde G; Clin Genitourin Cancer. 2016 May 27.
See more >>